DE60319210T2 - Verfahren zur virusproduktion - Google Patents

Verfahren zur virusproduktion Download PDF

Info

Publication number
DE60319210T2
DE60319210T2 DE60319210T DE60319210T DE60319210T2 DE 60319210 T2 DE60319210 T2 DE 60319210T2 DE 60319210 T DE60319210 T DE 60319210T DE 60319210 T DE60319210 T DE 60319210T DE 60319210 T2 DE60319210 T2 DE 60319210T2
Authority
DE
Germany
Prior art keywords
virus
temperature
adenovirus
culture
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60319210T
Other languages
German (de)
English (en)
Other versions
DE60319210D1 (de
Inventor
Liangzhi Rahway XIE
Charles F. Rahway GOOCHEE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE60319210D1 publication Critical patent/DE60319210D1/de
Publication of DE60319210T2 publication Critical patent/DE60319210T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60319210T 2002-03-29 2003-03-27 Verfahren zur virusproduktion Expired - Lifetime DE60319210T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36865402P 2002-03-29 2002-03-29
US368654P 2002-03-29
PCT/US2003/009269 WO2003085138A1 (en) 2002-03-29 2003-03-27 Methods of virus production

Publications (2)

Publication Number Publication Date
DE60319210D1 DE60319210D1 (de) 2008-04-03
DE60319210T2 true DE60319210T2 (de) 2009-02-12

Family

ID=28791896

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60319210T Expired - Lifetime DE60319210T2 (de) 2002-03-29 2003-03-27 Verfahren zur virusproduktion

Country Status (9)

Country Link
US (1) US7344873B2 (https=)
EP (1) EP1492891B1 (https=)
JP (1) JP4413012B2 (https=)
AT (1) ATE386824T1 (https=)
AU (1) AU2003226012B2 (https=)
CA (1) CA2478901A1 (https=)
DE (1) DE60319210T2 (https=)
ES (1) ES2299715T3 (https=)
WO (1) WO2003085138A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5352578B2 (ja) * 2007-05-04 2013-11-27 バクスター・インターナショナル・インコーポレイテッド ウイルスの増殖のための二段階温度プロフィール
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
CA2829774C (en) 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962424A (en) 1974-01-31 1976-06-08 Recherche Et Industrie Therapeutiques (R.I.T.) Live brovine adenovirus vaccines, preparation thereof and method of vaccination using them
US5618714A (en) * 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
CA2422882A1 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications

Also Published As

Publication number Publication date
EP1492891A4 (en) 2005-08-24
ATE386824T1 (de) 2008-03-15
EP1492891B1 (en) 2008-02-20
CA2478901A1 (en) 2003-10-16
AU2003226012B2 (en) 2007-05-24
AU2003226012A1 (en) 2003-10-20
US20050176146A1 (en) 2005-08-11
US7344873B2 (en) 2008-03-18
JP2005521423A (ja) 2005-07-21
ES2299715T3 (es) 2008-06-01
DE60319210D1 (de) 2008-04-03
WO2003085138A1 (en) 2003-10-16
JP4413012B2 (ja) 2010-02-10
EP1492891A1 (en) 2005-01-05

Similar Documents

Publication Publication Date Title
DE60037911T2 (de) Verfahren zur produktion von adenovirus
DE60121471T2 (de) Komplementierende zellinien
EP1427817B1 (de) Vermehrung von viren in zellkultur
DE10144906B4 (de) Verfahren zur großtechnischen Herstellung von Impfstoffen
DE69534902T2 (de) Rekombinanter viraler DNS Vektor zur Transfektion tierischer Zellen
DE60025701T2 (de) Vektoren und virale impfstoffe basierend auf rekombinantem schweine-adenovirus
DE69636055T2 (de) Adenovirale vektoren, die nicht von gruppe c adenovirus typen abgeleitet sind
KR102022952B1 (ko) 백시니아 바이러스의 생산을 위한 방법 및 조성물
Dong et al. Emergence of fatal European genotype CyHV-3/KHV in mainland China
DE69930250T3 (de) Verfahren zur herstellung von viren
DE60320520T3 (de) Verfahren zur amplifikation von einem poxvirus in serumfreien verhältnissen
Shen et al. Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1. 3)
Chen et al. Construction of a full-length infectious bacterial artificial chromosome clone of duck enteritis virus vaccine strain
CN119351466B (zh) 一株弓形虫基因敲除疫苗虫株的构建方法及其应用
CN106939320A (zh) 一种伪狂犬病毒js‑2012株感染性克隆质粒、构建方法与应用
DE60319210T2 (de) Verfahren zur virusproduktion
JP7548916B2 (ja) ウイルスの製造方法
DE69838644T2 (de) Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors
CN115806943B (zh) 双荧光标记的重组伪狂犬病病毒株及其构建方法和应用
DE60027364T2 (de) Adenovirus-mutanten mit deletiertem proteasegen, komplementierende zelllinien und entsprechende vektoren für den gentransfer
Kosutic-Gulija et al. Genetic heterogeneity of L-Zagreb mumps virus vaccine strain
EP2606128B1 (de) Permanente humane amniozyten zellinie zur herstellung von influenzaviren
TW202237831A (zh) 生產腺病毒之方法
Ning et al. Generation of recombinant Orf virus using an enhanced green fluorescent protein reporter gene as a selectable marker
Subramanian et al. Scaleable production of adenoviral vectors by transfection of adherent PER. C6 cells

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, N.J., US

8328 Change in the person/name/address of the agent

Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LUXEMBOURG, LU